Effect of L-Carnitine on the Limitation of Infarct Size in One-Month Postmyocardial Infarction Cases

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis

“…16 L-Carnitine has been shown to reduce infarct size (measured by reductions in cardiac enzymes) in numerous AMI clinical trials, leading to improvements in myocardial viability and salvage. 18,22,23 Furthermore, L-carnitine has been shown to significantly reduce VAs after AMI, which may partly explain the early significant 39% reduction in 5-day mortality (a prespecified secondary end point) in the Carnitine Ecocardiografia Digitalizzata Infarto Miocardico 2 (CEDIM 2) trial 24 ( De Pasquale et al, 15 1990 Davini et al, 14 1992 Jacoba et al, 18 1996 Rebuzzi et al, 22 1984 Xue et al, 25 2007 Iyer et al, 17 1999 Singh et al, 23 1996 Kobulia et al, 19 2002 Iliceto et al, 16 1995 Tarantini et al, 24 2006 Rizzon et al, 4 1989 vs 44 events; hazard ratio, 0.61; 95% CI, 0.37-0.98; P¼.041). 4,[20][21][22][23][24] These findings suggest that L-carnitine may reduce all-cause mortality, VAs, and anginal attacks in patients with AMI.…”

“…Of these, 13 studies were deemed eligible for inclusion ( Figure 1). 4,[14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Tables 1 and 2 (available online at http://www.mayoclinicproceedings.org) summarize the characteristics of the included studies and the risk of bias in the included trials. 4,[14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Table 3 (available online at http:// www.mayoclinicproceedings.org) summarizes the quality of the included trials.…”

“…4,[14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Tables 1 and 2 (available online at http://www.mayoclinicproceedings.org) summarize the characteristics of the included studies and the risk of bias in the included trials. 4,[14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Table 3 (available online at http:// www.mayoclinicproceedings.org) summarizes the quality of the included trials. 4,[14][15][16][17][18][19][20][21][22][23][24][25] Characteristics of Included Studies All the trials were comparison trials of L-carnitine compared with placebo or control in the AMI setting.…”

“…4,[14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Table 3 (available online at http:// www.mayoclinicproceedings.org) summarizes the quality of the included trials. 4,[14][15][16][17][18][19][20][21][22][23][24][25] Characteristics of Included Studies All the trials were comparison trials of L-carnitine compared with placebo or control in the AMI setting. All the background medications and baseline characteristics were statistically similar between the comparison groups in each trial except for that by De Pasquale et al 15 Trials enrolled a median of 96 patients (interquartile range, 20-2329 patients), with median followup of 2 months (interquartile range, 0.7-12 months).…”

“…Excluding the 5 smallest studies, 4,17,18,22,25 trials including a moderate number of mortality events (!10 events total) indicated a 34% reduction in all-cause mortality with L-carnitine compared with placebo or control (RR, 0.67; 95% CI, 0.42-1.07; P¼.09; I 2 ¼40%) ( Figure 7).…”